ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib

BACKGROUND: Osimertinib (AZD9291), a third generation mutation-selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (EGFR-TKI), is an approved drug for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations or those harboring resistant T790M mutation. Unfor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: Li, Yiting, Zang, Hongjing, Qian, Guoqing, Owonikoko, Taofeek K., Ramalingam, Suresh R., Sun, Shi-Yong
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7050394/
https://ncbi.nlm.nih.gov/pubmed/31821539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32655
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares